Kimia Biosciences Ltd
Kimia Biosciences Ltd (KIMIABL) last reported results for the quarter ended Jun 2026, with sales of ₹20.72 crore and net profit of ₹0.36 crore. The stock last traded at ₹32, a market capitalisation of ₹151 crore, on a P/E of 21.0. Over the past 52 weeks the stock has ranged between ₹23.2 and ₹43.3. Figures are as of 6 Oct 2026 and are not real time.
Kimia Biosciences Ltd share price and key metrics
- Current price
- ₹32
- Market cap
- ₹151 cr
- Stock P/E
- 21.0
- Book value
- ₹3.75
- ROE
- 53.7%
- ROCE
- 25.1%
- Dividend yield
- 0.00%
- 52w high / low
- 43.3/23.2
Metrics as of 6 Oct 2026. Not real time.
Track Kimia Biosciences Ltd
Cruxal reads every Kimia Biosciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Kimia Biosciences Ltd growth and returns
- 10 Years
- 90%
- 5 Years
- -3%
- 3 Years
- -4%
- TTM
- -7%
- 10 Years
- 14%
- 5 Years
- 8%
- 3 Years
- 43%
- TTM
- -18%
- 10 Years
- 11%
- 5 Years
- -5%
- 3 Years
- -6%
- 1 Year
- -14%
- 10 Years
- %
- 5 Years
- -1%
- 3 Years
- 54%
- Last Year
- 54%
Kimia Biosciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹20.72 cr, down 12.1% from ₹23.58 cr a year earlier. Net profit was ₹0.36 cr, down 40.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 28.18 | 30.1 | 38.24 | 23.58 | 34 | 30.1 | 27.2 | 20.72 |
| Expenses | 24.81 | 25.1 | 30.06 | 21.05 | 31.48 | 23.54 | 24.54 | 18.37 |
| Operating profit | 3.37 | 5 | 8.18 | 2.53 | 2.52 | 6.56 | 2.66 | 2.35 |
| OPM % | 11.96% | 16.61% | 21.39% | 10.73% | 7.41% | 21.79% | 9.78% | 11.34% |
| Other income | 0.37 | 0.42 | 0.44 | 0.85 | -0.33 | 0.1 | 1.01 | 0.08 |
| Interest | 1.04 | 1.01 | 1.4 | 1.75 | 0.27 | 0.75 | 0.75 | 0.83 |
| Depreciation | 0.79 | 0.82 | 0.88 | 0.94 | 0.97 | 0.85 | 1.16 | 1.11 |
| Profit before tax | 1.91 | 3.59 | 6.34 | 0.69 | 0.95 | 5.06 | 1.76 | 0.49 |
| Tax % | 15.71% | -27.30% | 68.61% | 13.04% | -7.37% | -7.71% | 78.98% | 26.53% |
| Net profit | 1.61 | 4.57 | 1.99 | 0.6 | 1.02 | 5.44 | 0.37 | 0.36 |
| EPS (₹) | 0.34 | 0.97 | 0.42 | 0.13 | 0.22 | 1.15 | 0.08 | 0.08 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Kimia Biosciences Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1 | 76 | 94 | 106 | 133 | 125 | 129 | 105 | 119 | 115 | 112 |
| Operating profit | -1 | 2 | 6 | 4 | 8 | 1 | -5 | -0 | 20 | 14 | 14 |
| OPM % | -56% | 3.2% | 6% | 4.2% | 6% | 0.5% | -3.9% | -0.5% | 17% | 12% | 13% |
| Net profit | -1 | 2 | 4 | 1 | 5 | -4 | -9 | -5 | 10 | 7 | 7 |
| EPS (₹) | -1.26 | 2.26 | 2.64 | 0.30 | 1.08 | -0.78 | -1.98 | -1.12 | 2.03 | 1.57 | 1.53 |
TTM is the trailing twelve months to the most recent quarter.
Kimia Biosciences Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 7 | 1 | 1 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | -12 | 0 | 4 | 9 | 14 | 10 | 1 | -4 | 5 | 13 |
| Borrowings | 14 | 34 | 31 | 34 | 45 | 41 | 53 | 44 | 33 | 35 |
| Other liabilities | 3 | 22 | 29 | 38 | 43 | 54 | 63 | 56 | 68 | 51 |
| Total liabilities | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 100 | 111 | 103 |
| Fixed assets | 7 | 13 | 16 | 18 | 28 | 35 | 34 | 32 | 33 | 37 |
| CWIP | 3 | 2 | 2 | 6 | 6 | 0 | 1 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 2 | 43 | 48 | 62 | 72 | 74 | 87 | 68 | 78 | 66 |
| Total assets | 12 | 58 | 65 | 86 | 107 | 109 | 121 | 100 | 111 | 103 |
As reported by the company. Total assets equal total liabilities by construction.
Kimia Biosciences Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -1 | -7 | -3 | 0 | 6 | 8 | -7 | 15 | 21 | 11 |
| Cash from investing | -6 | -2 | -2 | -9 | -14 | -1 | -3 | -1 | -5 | -8 |
| Cash from financing | 7 | 10 | 4 | 8 | 8 | -8 | 10 | -13 | -17 | -3 |
| Net cash flow | 0 | 0 | -0 | 0 | 0 | -0 | -0 | -0 | 0 | 0 |
| Free cash flow | -7 | -10 | -5 | -9 | -8 | 6 | -10 | 13 | 17 | 3 |
| CFO / operating profit | 85% | -287% | -45% | 5% | 71% | 1,281% | 136% | -3,021% | 105% | 76% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Kimia Biosciences Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -10% | 10% | 16% | 9% | 16% | -2% | -12% | -4% | 42% | 25% |
| Debtor days | 20 | 141 | 113 | 128 | 115 | 88 | 87 | 96 | 113 | 93 |
| Inventory days | 615 | 59 | 83 | 92 | 89 | 146 | 183 | 149 | 178 | 137 |
| Days payable | 511 | 120 | 91 | 121 | 116 | 159 | 177 | 194 | 260 | 220 |
| Cash conversion cycle | 124 | 80 | 105 | 100 | 88 | 76 | 93 | 51 | 31 | 10 |
| Working capital days | -1,358 | 48 | 62 | 73 | 53 | 31 | 16 | -30 | -22 | 5 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Kimia Biosciences Ltd shareholding pattern
Promoters held 74.94% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.38%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
| DIIs | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% | 0.38% |
| Public | 24.67% | 24.68% | 24.67% | 24.68% | 24.68% | 24.68% | 24.68% | 24.68% |
| No. of shareholders | 12,179 | 12,231 | 12,278 | 12,200 | 12,616 | 12,751 | 12,775 | 12,775 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Kimia Biosciences Ltd corporate filings
- Kimia Biosciences Limited holds its AGM on 28 September 2026, approving key board changes including reappointment of existing directors and appointment of new independent directors, with no immediate financial disclosures or strategic events announced.Company Updatelow impact
Cruxal's analysis: Kimia Biosciences Limited conducted its 33rd AGM on 28 September 2026, where the…
Read the full analysis - Kimia Biosciences Limited's AGM results confirm strong shareholder support for key resolutions, with over 99.99% approval for financial statements, reappointment of directors, and other strategic resolutions, indicating stable governance and positive investor sentiment.AGM/EGMmedium impact
Cruxal's analysis: Kimia Biosciences Limited has successfully conducted its 33rd AGM on September 28, 2026…
Read the full analysis - Kimia Biosciences Limited Concludes 33rd Annual General Meeting; Seeks Shareholder Approval for Enhanced Borrowing and Investment LimitsAGM/EGMmedium impact
Cruxal's analysis: Kimia Biosciences Limited has concluded its 33rd Annual General Meeting, where…
Read the full analysis - Intimation of Trading Window closure for quarter and half year ending September 30, 2026Insider Trading / SASTlow impact
- Kimia Biosciences Limited Announces 33rd Annual General Meeting (AGM) Scheduled for September 28, 2026Company Updatelow impact
Cruxal's analysis: Kimia Biosciences Limited has issued a formal notice for its 33rd Annual General Meeting…
Read the full analysis - Kimia Biosciences Limited Announces 33rd AGM and Submits Annual Report for FY 2025-26AGM/EGMmedium impact
Cruxal's analysis: Kimia Biosciences Limited has submitted its 33rd Annual Report for the financial year…
Read the full analysis - Kimia Biosciences Announces Board Reconstitution and Seeks Shareholder Approval for Enhanced Borrowing and Investment LimitsOtherslow impact
Cruxal's analysis: Kimia Biosciences Limited has announced a board restructuring, including the…
Read the full analysis - Kimia Biosciences Limited Reports Q1 FY2027 Financial Results with Net Loss of 0.02 croreCompany Updatemedium impact
Cruxal's analysis: Kimia Biosciences Limited reported its standalone financial results for the quarter ended…
Read the full analysis - Kimia Biosciences Q1 FY27 Results: Revenue and Profit Decline Sharply YoYBoard Meetinghigh impact
Cruxal's analysis: Kimia Biosciences Limited reported a significant decline in financial performance for the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.